• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Industry Briefs

Industry Briefs

May 7, 2018

CTTI Planning Recommendations on Investigators, Decentralized Trials and Mobile Technologies

The Clinical Trials Transformation Initiative is developing several new sets of recommendations relating to clinical trials — on the qualification of investigators, the potential legal and regulatory hurdles to decentralized trials and obstacles to incorporating mobile technology, according to its 2017 annual report. In the report marking the organizations 10th anniversary, CTTI also aims to develop toolkits personalized to stakeholders to help with adoption of its recommendations and says it will share case studies with the clinical research community to show how the resources can be applied to improve processes and outcomes. The initiative issued five new sets of recommendations last year including: developing novel endpoints generated by mobile technology; making registries into reusable platforms for conducting clinical trials; providing for pregnancy testing in clinical trials; strengthening pediatric trials in antibacterial drug development; and strengthening the investigator site community. Read the CTTI annual report here.

More Women Needed In Heart Disease Clinical Trials, Study Finds

Women are underrepresented in clinical trials for heart diseases when considering their prevalence within each disease population, according to study findings reported in the Journal of the American College of Cardiology. To determine the percentage of women enrolled, researchers looked at 36 approvals for 35 drugs for diseases such as acute coronary syndrome/myocardial infarction, coronary artery disease, heart failure, atrial fibrillation and hypertension, to determine the percentage of women enrolled. Researchers found that just 34 percent were women. The researchers concluded that factors prior to screening, such as the ability of a candidate to participate and the identification of potential trial participants, may be the reasons behind the low number of women, as the data in this latest study shows that the low number of enrolled women reflects the lower number of women referred for pre-trial participation screening.

Clinical Trial Participation Brings Hefty Travel Burden, Study Finds

A study published in The Oncologist found that patients who enroll in clinical trials for treatment experience a heavy travel burden. The study analyzed the data of 1,600 patients who enrolled in clinical trials between 1993 and 2014, measuring the distance they traveled from their home to the site of the study and finding that, overall, patients traveled a median distance of 25.8 miles. Patients in NIH-sponsored studies had to go even greater distances, incurring 39.4 miles on average, and patients in phase 1 studies had to travel farther than any other type, navigating a median of 41.2 miles to participate in them, the study said.

Academic Institutions Slow With Clinical Trial Transparency Requirements, Study Finds

Academic institutions have been slow to get on track with stricter requirements released by the HHS and NIH for clinical trial registration and reporting, according to a study by the Johns Hopkins Bloomberg School of Public Health. The study, published May 2 in the BMC Medicine journal, looked at survey data from over 350 U.S. academic institutions that conduct clinical trials. The researchers found that relatively few had enough staff or necessary policies in place to comply with the new requirements. Before the stricter requirements came into effect, the researchers conducted an online survey of academic institutions registered on ClinicalTrials.gov to determine how prepared they were for the new requirements. Of the 783 eligible accounts contacted, they received responses from 366. Only 43 percent of the accounts had a policy for clinical trial registration, and only 35 percent had a policy on reporting trial results. Survey respondents frequently reported devoting almost no staff time to the website’s registration and reporting requirements, with a median full-time staff equivalent of 0.08, or just a few hours per week devoted to regulatory compliance.

CSDR Partners With Non-Profits to Expand Data-Sharing to Academic Clinical Trial Data

Online clinical trial data resource Clinical Study Data Request (CSDR) has launched data-sharing collaborations with four nonprofits to expand the services it offers to researchers. CDSR will partner with the Wellcome Trust, the Medical Research Council, Cancer Research UK and the Bill & Melinda Gates Foundation. The groups will help CSDR broaden its offerings to include academic-led clinical trial data on top of the patient-level clinical data it already offers.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing